Cabinet defers FDI norms on pharma and housing Illustrative image – not actual.

The Cabinet has deferred the consideration of proposals to relax foreign direct investment norms in the housing sector and to reduce the FDI cap in the pharma segment. 


The Department of Industrial Policy and Promotion (DIPP) has proposed reducing the FDI cap in 'rare or critical pharma verticals' to 49 per cent from 100 per cent. The department also proposed conditions for foreign firms such as mandatory investment in research and development and non-compete clauses in the shareholders pact.


The concern is that with MNCs taking control of Indian firms, there can be a reduction in the supply of vaccines, injectables, particularly for cancer and active pharmaceutical ingredients.


Currently, India permits 100 per cent FDI in the pharma sector through automatic approval route in new projects, while for existing pharma companies, it is allowed only after approval from the Foreign Investment Promotion Board.


In the housing sector, the DIPP has proposed relaxing FDI norms, including easing conditions for exit for foreign investors before the three year lock-in period.


 

← All latest storiesBack to top →